The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
ConclusionsTreatment with biologic or tofacitinib appears to be well-tolerated with respect to CV outcomes in these patients.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Autoimmune Disease | Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Heart | Rheumatology | Study